Impact of Patient Engagement on Product Development

admedicum is pleased to announce a blog series on topics in patient engagement relevant to those in the pharmaceutical industry. This is the fourth part of the series. 

 

Part 1: Opportunities and Risks of Patient Engagement

Part 2: Impact on Core Area I - Strategy and Organization

Part 3: Impact on Core Area II - Research and Portfolio Management 

 

-----------------------------------------------------------------------------------------------------------------

Part 4: Impact of Patient Engagement on Product Development

 

As elaborated earlier, it is important to involve patients early in clinical development. Examples show that this can even start with the research question and the design of the studies (Nourissier 2015; Reimann 2015). A study design that is acceptable to patients may not only be important for the actual relevance of a clinical study, but also for the speed of recruitment and protocol-compliant retention during the study. Patient involvement can therefore directly influence time to market.


Patients as innovators - Patient needs as innovation drivers


Very often, patients and their relatives are experts in their own disease, especially if they live with a chronic illness. A lack of, or inadequate, supply of care sometimes forces them to find their own solutions. Attentive listening and understanding of unmet patient needs can become a source of innovative developments.
Patient organizations in the USA and Europe (e.g. in the fields of cancer, dementia, Parkinson's disease, cystic fibrosis, Duchenne muscular dystrophy and other rare diseases) are increasingly becoming innovators themselves and transforming promising findings from basic research into systematic development. Experienced pharmaceutical partners are required to further continue this work.


This creates opportunities for pharmaceutical companies to develop new therapeutic options and bring them to market them. In addition, insufficient therapy adherence or a lack of tangible benefits of existing products can be starting points for product modifications or "beyond-the-pill" services that go above and beyond the mere provision of drugs.


Pharmaceutical companies that consistently orient themselves to the needs of patients, rethinking traditional product development, can be more successful in achieving sustainable patient benefits.

 

 

Continue reading:

Part 5: Impact of Patient Engagement on Market Access and Services

 

Go back